Recombinant growth hormone treatment in short patients with thalassemia major

Results after 24 and 36 months

L. Cavallo, A. Acquafredda, C. Zecchino, V. De Sanctis, M. Cisternino, M. C. Nicoletti, M. Galati, F. Massolo

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Treatment with recombinant growth hormone (rhGH), 0.6 IU/kg/week s.c., previously successfully conducted for one year, was continued in 15 (Group A) and 8 (Group B) short thalassemia major patients with reduced GH reserve, for two and three years, respectively. In Group A, height for chronological age (Ht SDSCA) increased significantly (p=0.021) from the start of treatment, but the positive effect was only apparent because of the concomitant slight worsening of height for bone age (Ht SDSBA). Median ΔHt SDSCA/ΔHt SDSBA was CA nor Ht SDSBA differed statistically from starting values, the former having a positive trend and the latter a negative one. Median ΔHt SDSCA/ΔHt SDSBA was 0.92 with respect to the start, and 0.94 with respect to the end of the second year. IGF-I levels increased significantly (p=0.043) with respect to starting values. Our data show that the encouraging results described from the first year of rhGH treatment did not persist during the second and third years, and we conclude that this is because increase in bone age with continued treatment is equal to, or slightly greater than the height age increase. We propose that patients with thalassemia major with short stature should receive rhGH treatment for only one year, and that more prolonged treatment should be reserved for selected adolescents who have psychological problems due to shortness; for these patients growth acceleration could represent the main goal, even if this leads to a substantially unchanged or slightly decreased final height.

Original languageEnglish
Pages (from-to)1133-1137
Number of pages5
JournalJournal of Pediatric Endocrinology and Metabolism
Volume14
Issue number8
Publication statusPublished - 2001

Fingerprint

beta-Thalassemia
Growth Hormone
Therapeutics
Bone and Bones
Insulin-Like Growth Factor I
Psychology
Growth

Keywords

  • Recombinant growth hormone therapy
  • Thalassemia major

ASJC Scopus subject areas

  • Endocrinology
  • Pediatrics, Perinatology, and Child Health

Cite this

Cavallo, L., Acquafredda, A., Zecchino, C., De Sanctis, V., Cisternino, M., Nicoletti, M. C., ... Massolo, F. (2001). Recombinant growth hormone treatment in short patients with thalassemia major: Results after 24 and 36 months. Journal of Pediatric Endocrinology and Metabolism, 14(8), 1133-1137.

Recombinant growth hormone treatment in short patients with thalassemia major : Results after 24 and 36 months. / Cavallo, L.; Acquafredda, A.; Zecchino, C.; De Sanctis, V.; Cisternino, M.; Nicoletti, M. C.; Galati, M.; Massolo, F.

In: Journal of Pediatric Endocrinology and Metabolism, Vol. 14, No. 8, 2001, p. 1133-1137.

Research output: Contribution to journalArticle

Cavallo, L, Acquafredda, A, Zecchino, C, De Sanctis, V, Cisternino, M, Nicoletti, MC, Galati, M & Massolo, F 2001, 'Recombinant growth hormone treatment in short patients with thalassemia major: Results after 24 and 36 months', Journal of Pediatric Endocrinology and Metabolism, vol. 14, no. 8, pp. 1133-1137.
Cavallo L, Acquafredda A, Zecchino C, De Sanctis V, Cisternino M, Nicoletti MC et al. Recombinant growth hormone treatment in short patients with thalassemia major: Results after 24 and 36 months. Journal of Pediatric Endocrinology and Metabolism. 2001;14(8):1133-1137.
Cavallo, L. ; Acquafredda, A. ; Zecchino, C. ; De Sanctis, V. ; Cisternino, M. ; Nicoletti, M. C. ; Galati, M. ; Massolo, F. / Recombinant growth hormone treatment in short patients with thalassemia major : Results after 24 and 36 months. In: Journal of Pediatric Endocrinology and Metabolism. 2001 ; Vol. 14, No. 8. pp. 1133-1137.
@article{ddb098835519450289d641ad64e5b3f7,
title = "Recombinant growth hormone treatment in short patients with thalassemia major: Results after 24 and 36 months",
abstract = "Treatment with recombinant growth hormone (rhGH), 0.6 IU/kg/week s.c., previously successfully conducted for one year, was continued in 15 (Group A) and 8 (Group B) short thalassemia major patients with reduced GH reserve, for two and three years, respectively. In Group A, height for chronological age (Ht SDSCA) increased significantly (p=0.021) from the start of treatment, but the positive effect was only apparent because of the concomitant slight worsening of height for bone age (Ht SDSBA). Median ΔHt SDSCA/ΔHt SDSBA was CA nor Ht SDSBA differed statistically from starting values, the former having a positive trend and the latter a negative one. Median ΔHt SDSCA/ΔHt SDSBA was 0.92 with respect to the start, and 0.94 with respect to the end of the second year. IGF-I levels increased significantly (p=0.043) with respect to starting values. Our data show that the encouraging results described from the first year of rhGH treatment did not persist during the second and third years, and we conclude that this is because increase in bone age with continued treatment is equal to, or slightly greater than the height age increase. We propose that patients with thalassemia major with short stature should receive rhGH treatment for only one year, and that more prolonged treatment should be reserved for selected adolescents who have psychological problems due to shortness; for these patients growth acceleration could represent the main goal, even if this leads to a substantially unchanged or slightly decreased final height.",
keywords = "Recombinant growth hormone therapy, Thalassemia major",
author = "L. Cavallo and A. Acquafredda and C. Zecchino and {De Sanctis}, V. and M. Cisternino and Nicoletti, {M. C.} and M. Galati and F. Massolo",
year = "2001",
language = "English",
volume = "14",
pages = "1133--1137",
journal = "Journal of Pediatric Endocrinology and Metabolism",
issn = "0334-018X",
publisher = "Walter de Gruyter GmbH & Co. KG",
number = "8",

}

TY - JOUR

T1 - Recombinant growth hormone treatment in short patients with thalassemia major

T2 - Results after 24 and 36 months

AU - Cavallo, L.

AU - Acquafredda, A.

AU - Zecchino, C.

AU - De Sanctis, V.

AU - Cisternino, M.

AU - Nicoletti, M. C.

AU - Galati, M.

AU - Massolo, F.

PY - 2001

Y1 - 2001

N2 - Treatment with recombinant growth hormone (rhGH), 0.6 IU/kg/week s.c., previously successfully conducted for one year, was continued in 15 (Group A) and 8 (Group B) short thalassemia major patients with reduced GH reserve, for two and three years, respectively. In Group A, height for chronological age (Ht SDSCA) increased significantly (p=0.021) from the start of treatment, but the positive effect was only apparent because of the concomitant slight worsening of height for bone age (Ht SDSBA). Median ΔHt SDSCA/ΔHt SDSBA was CA nor Ht SDSBA differed statistically from starting values, the former having a positive trend and the latter a negative one. Median ΔHt SDSCA/ΔHt SDSBA was 0.92 with respect to the start, and 0.94 with respect to the end of the second year. IGF-I levels increased significantly (p=0.043) with respect to starting values. Our data show that the encouraging results described from the first year of rhGH treatment did not persist during the second and third years, and we conclude that this is because increase in bone age with continued treatment is equal to, or slightly greater than the height age increase. We propose that patients with thalassemia major with short stature should receive rhGH treatment for only one year, and that more prolonged treatment should be reserved for selected adolescents who have psychological problems due to shortness; for these patients growth acceleration could represent the main goal, even if this leads to a substantially unchanged or slightly decreased final height.

AB - Treatment with recombinant growth hormone (rhGH), 0.6 IU/kg/week s.c., previously successfully conducted for one year, was continued in 15 (Group A) and 8 (Group B) short thalassemia major patients with reduced GH reserve, for two and three years, respectively. In Group A, height for chronological age (Ht SDSCA) increased significantly (p=0.021) from the start of treatment, but the positive effect was only apparent because of the concomitant slight worsening of height for bone age (Ht SDSBA). Median ΔHt SDSCA/ΔHt SDSBA was CA nor Ht SDSBA differed statistically from starting values, the former having a positive trend and the latter a negative one. Median ΔHt SDSCA/ΔHt SDSBA was 0.92 with respect to the start, and 0.94 with respect to the end of the second year. IGF-I levels increased significantly (p=0.043) with respect to starting values. Our data show that the encouraging results described from the first year of rhGH treatment did not persist during the second and third years, and we conclude that this is because increase in bone age with continued treatment is equal to, or slightly greater than the height age increase. We propose that patients with thalassemia major with short stature should receive rhGH treatment for only one year, and that more prolonged treatment should be reserved for selected adolescents who have psychological problems due to shortness; for these patients growth acceleration could represent the main goal, even if this leads to a substantially unchanged or slightly decreased final height.

KW - Recombinant growth hormone therapy

KW - Thalassemia major

UR - http://www.scopus.com/inward/record.url?scp=0034794175&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034794175&partnerID=8YFLogxK

M3 - Article

VL - 14

SP - 1133

EP - 1137

JO - Journal of Pediatric Endocrinology and Metabolism

JF - Journal of Pediatric Endocrinology and Metabolism

SN - 0334-018X

IS - 8

ER -